Synapse

← Steven A. Rosenberg

Papers by Steven A. Rosenberg

Page 7 · newest first

  1. Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer TherapyJournal of Immunotherapy · 2004
  2. Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer TherapyThe Journal of Immunology · 2004
  3. Selective Growth, In Vitro and In Vivo, of Individual T Cell Clones from Tumor-Infiltrating Lymphocytes Obtained from Patients with MelanomaThe Journal of Immunology · 2004
  4. Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic MelanomaJournal of Immunotherapy · 2004
  5. Immunization of HLA-A*0201 and/or HLA-DPβ1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 AntigenJournal of Immunotherapy · 2004
  6. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytesProceedings of the National Academy of Sciences · 2004
  7. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapyBlood · 2004
  8. Immunization of Patients with the hTERT:540-548 Peptide Induces Peptide-Reactive T Lymphocytes That Do Not Recognize Tumors Endogenously Expressing TelomeraseClinical Cancer Research · 2004
  9. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancerJournal of Leukocyte Biology · 2004
  10. T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene ProductThe Journal of Immunology · 2004
  11. Development of effective immunotherapy for the treatment of patients with cancerJournal of the American College of Surgeons · 2004
  12. Shedding Light on Immunotherapy for CancerNew England Journal of Medicine · 2004
  13. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 ⁺ T CellsProceedings of the National Academy of Sciences · 2004
  14. Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes From a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC ExpressionJournal of Immunotherapy · 2004
  15. A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell CarcinomaJournal of Immunotherapy · 2004
  16. Phenotypic and Functional Maturation of Tumor Antigen-Reactive CD8+ T Lymphocytes in Patients Undergoing Multiple Course Peptide VaccinationJournal of Immunotherapy · 2003
  17. High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma AntigensThe Journal of Immunology · 2003
  18. Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic MelanomaJournal of Immunotherapy · 2003
  19. Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T CellsThe Journal of Experimental Medicine · 2003
  20. Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology · 2003
  21. A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine · 2003
  22. Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated AntigensJournal of Immunotherapy · 2003
  23. Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma PatientsJournal of Immunotherapy · 2003
  24. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaProceedings of the National Academy of Sciences · 2003
  25. Inability to Immunize Patients with Metastatic Melanoma Using Plasmid DNA Encoding the gp100 Melanoma-Melanocyte AntigenHuman Gene Therapy · 2003
  26. Interleukin-2–Independent Proliferation of Human Melanoma-Reactive T Lymphocytes Transduced With an Exogenous IL-2 Gene Is Stimulation DependentJournal of Immunotherapy · 2003
  27. Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II MoleculesThe Journal of Immunology · 2003
  28. Continuous Intravenous Administration of Live Genetically Modified Salmonella Typhimurium in Patients With Metastatic MelanomaJournal of Immunotherapy · 2003
  29. Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1The Journal of Immunology · 2003
  30. Parathyroid Hormone-Related Protein and Hypercalcemia in Patients With Metastatic MelanomaAmerican Journal of Clinical Oncology · 2003
  31. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens.Journal of Immunotherapy · 2003
  32. Multiple HLA Class II-Restricted Melanocyte Differentiation Antigens Are Recognized by Tumor-Infiltrating Lymphocytes from a Patient with MelanomaThe Journal of Immunology · 2002
  33. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience · 2002
  34. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium.2002
  35. Functional Heterogeneity of Vaccine-Induced CD8+ T CellsThe Journal of Immunology · 2002
  36. A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic MelanomaJournal of Immunotherapy · 2002
  37. Frequency of MART-1/MelanA and gp100/PMel17-Specific T Cells in Tumor Metastases and Cultured Tumor-Infiltrating LymphocytesJournal of Immunotherapy · 2002
  38. Antitumor Effects in Mice of the Intravenous Injection of Attenuated Salmonella TyphimuriumJournal of Immunotherapy · 2002
  39. Mobilization of Dendritic Cell Precursors in Patients With Cancer by Flt3 Ligand Allows the Generation of Higher Yields of Cultured Dendritic CellsJournal of Immunotherapy · 2002
  40. Identification of BING-4 Cancer Antigen Translated From an Alternative Open Reading Frame of a Gene in the Extended MHC Class II Region Using Lymphocytes From a Patient With a Durable Complete Regression Following ImmunotherapyThe Journal of Immunology · 2002
  41. Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic MelanomaJournal of Clinical Oncology · 2002
  42. Pre-Existing Immunity to Tyrosinase-Related Protein (TRP)-2, a New TRP-2 Isoform, and the NY-ESO-1 Melanoma Antigen in a Patient with a Dramatic Response to ImmunotherapyThe Journal of Immunology · 2002
  43. Safety and Efficacy of High-Dose Interleukin-2 Therapy in Patients With Brain MetastasesJournal of Immunotherapy · 2002
  44. Transduction of an IL-2 Gene into Human Melanoma-Reactive Lymphocytes Results in Their Continued Growth in the Absence of Exogenous IL-2 and Maintenance of Specific Antitumor ActivityThe Journal of Immunology · 2001
  45. Progress in the development of immunotherapy for the treatment of patients with cancerJournal of Internal Medicine · 2001
  46. Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic MelanomaJournal of Clinical Oncology · 2001
  47. Short-Term Kinetics of Tumor Antigen Expression in Response to VaccinationThe Journal of Immunology · 2001
  48. Lack of Retroperitoneal Lymphadenopathy Predicts Survival of Patients With Metastatic Renal Cell CarcinomaThe Journal of Urology · 2001
  49. Identification of a New Shared HLA-A2.1 Restricted Epitope From the Melanoma Antigen TyrosinaseJournal of Immunotherapy · 2001
  50. Kinetics of TCR Use in Response to Repeated Epitope-Specific ImmunizationThe Journal of Immunology · 2001